ADAR1 Capital Management’s Structure Therapeutics GPCR Stock Holding History

ADAR1 Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$939K	Buy	+17,500	New	+$774K	0.04%	174
2025 Q4	–	Sell	-15,200	Closed	-$426K	–	277
2025 Q3	$426K	Buy	15,200 +200	+1%	+$3.98K	0.04%	147
2025 Q2	$311K	Sell	15,000 -20,619	-58%	-$453K	0.05%	136
2025 Q1	$617K	Buy	35,619 +300	+0.8%	+$7.35K	0.11%	92
2024 Q4	$958K	Buy	+35,319	New	+$1.25M	0.19%	80
2024 Q3	–	Sell	-1,516	Closed	-$59.5K	–	306
2024 Q2	$59.5K	Sell	1,516 -984	-39%	-$40.4K	0.01%	186
2024 Q1	$107K	Sell	2,500 -1,500	-38%	-$63.3K	0.02%	148
2023 Q4	$163K	Buy	+4,000	New	+$229K	0.06%	87

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ADAR1 Capital Management's GPCR Position: Q2 2026 in Review

ADAR1 Capital Management opened a new position in Structure Therapeutics (GPCR) in Q2 2026: 17,500 shares worth $939K. The stake represents 0.04% of the portfolio and ranks #174 among its holdings. This is a return to the name: ADAR1 Capital Management previously reported a position in GPCR as recently as Q3 2025.

ADAR1 Capital Management first reported a position in GPCR in Q4 2023 and has held it in 8 quarters since. The position peaked at $958K in Q4 2024. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

ADAR1 Capital Management held 17,500 shares of Structure Therapeutics worth $939K as of Q2 2026.
Structure Therapeutics was a new ADAR1 Capital Management position in Q2 2026.
Structure Therapeutics made up 0.04% of ADAR1 Capital Management's portfolio in Q2 2026, its #174 holding.
ADAR1 Capital Management first reported a position in Structure Therapeutics in Q4 2023 and has held it in 8 quarters since.
ADAR1 Capital Management's Structure Therapeutics position peaked at $958K in Q4 2024.
191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.